The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSchroder Income Growth Fund Regulatory News (SCF)

Share Price Information for Schroder Income Growth Fund (SCF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 290.00
Bid: 284.00
Ask: 287.00
Change: 5.50 (1.93%)
Spread: 3.00 (1.056%)
Open: 286.00
High: 290.00
Low: 285.00
Prev. Close: 284.50
SCF Live PriceLast checked at -
Schroder Income Growth is an Investment Trust

To provide real growth of income, being growth of income in excess of the rate of inflation, and capital growth as a consequence of the rising income primarily in UK equities.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results analysis from Kepler Trust Intelligence

27 Oct 2023 10:55

RNS Number : 5713R
Schroder Income Growth Fund PLC
27 October 2023
 

Schroder Income Growth (SCF)

27/10/2023

Results analysis from Kepler Trust Intelligence

Schroder Income and Growth (SCF) has published results for the full year period ending 31/08/2023. Over this period, the trust saw NAV total returns of 4.2% and a share price total return of -3.0%, which compares to 5.2% total return from the FTSE All-Share Index. NAV total returns remain comfortably ahead of the index since Sue Noffke took over management in 2011, with the trust delivering 128.5% compared to 103.5% for the benchmark.

The board has also increased the dividend for the 28th year running, 13.2p to 13.8p per share, an increase of 4.6%. The increase came despite a fall in the total income received from the portfolio, as the trust utilised its revenue reserves to help fulfil its primary objective of real growth of income above the levels of inflation over the longer term. 

Kepler View

SCF focuses on generating real growth, in both the income and capital over the long run. So, while short term performance may be a little disappointing during a tough period for the small and mid-caps which the trust is usually overweight, its long-term performance remains very strong, outperforming the benchmark by roughly 25%, since 2011, when Sue Noffke took over management. Despite being out of favour over the short term, we think exposure to medium and small companies should help deliver income and capital growth over time.

The long-term outperformance has been driven by astute stock selection in the UK medium and small cap space, but is also down to the way Sue and her team focus on exploiting market inefficiencies through companies they believe boast strong fundamentals that the market has failed to value appropriately. The diversity of the characteristics associated with different stocks, be that income generation or low correlation against inflation, means the underlying portfolio is designed to benefit from multiple forms of returns in a cycle and to perform in a variety of market environments.

Over the period, SCF benefited from strong performance from Whitbread, Hollywood Bowl and Pets at Home, and not owning a number of staples companies such as Diageo or Imperial Brands. The underperformance against the benchmark came primarily from the omission of some strongly performing industrial names, and its larger weighting to basic material companies compared to the index. While a larger allocation to medium and smaller sized companies has helped SCF's performance historically, returns have lagged those of the larger FTSE 100 more recently, which hurt performance.

We think that Sue and the team's high-conviction approach to running the portfolio has rewarded investors well over various time horizons and is an attractive proposition for income investors looking for real growth in income and capital over the long term. We also think that UK equity valuations are very cheap versus its history and other equity markets, so the propensity for equities to return to long-term average valuations, or 'mean reversion', could, in conjunction with SCF's wide discount, present an opportunity for long-term patient investors.

 

CLICK HERE TO READ THE FULL REPORT  Visit Kepler Trust Intelligence for more high quality independent investment trust research.

Important information

This report has been issued by Kepler Partners LLP. The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.

Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.

The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's Conflict of Interest policy is available on request.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 70 Conduit Street, London W1S 2GF with registered number OC334771.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAGCBDGDUDDGXR
Date   Source Headline
3rd May 202410:58 amRNSNet Asset Value(s)
2nd May 202410:45 amRNSNet Asset Value(s)
1st May 20241:58 pmRNSPortfolio Update
1st May 202410:42 amRNSNet Asset Value(s)
30th Apr 20245:28 pmRNSTotal Voting Rights
30th Apr 20244:18 pmRNSDirector/PDMR Shareholding
30th Apr 20242:00 pmRNSDirector/PDMR Shareholding
30th Apr 20241:59 pmRNSBlock listing Interim Review
30th Apr 202410:22 amRNSNet Asset Value(s)
30th Apr 20249:22 amRNSResults analysis from Kepler Trust Intelligence
29th Apr 202410:25 amRNSNet Asset Value(s)
29th Apr 20247:00 amRNSHalf-year Report
26th Apr 202410:47 amRNSNet Asset Value(s)
25th Apr 202410:46 amRNSNet Asset Value(s)
24th Apr 202410:28 amRNSNet Asset Value(s)
23rd Apr 202411:10 amRNSNet Asset Value(s)
22nd Apr 202410:36 amRNSNet Asset Value(s)
19th Apr 202410:19 amRNSNet Asset Value(s)
18th Apr 202410:18 amRNSNet Asset Value(s)
17th Apr 202410:38 amRNSNet Asset Value(s)
16th Apr 20244:38 pmRNSTransaction in Own Shares
16th Apr 202410:37 amRNSNet Asset Value(s)
15th Apr 20244:35 pmRNSPortfolio Update
15th Apr 202411:41 amRNSNet Asset Value(s)
12th Apr 202411:04 amRNSNet Asset Value(s)
11th Apr 202410:30 amRNSNet Asset Value(s)
10th Apr 202410:26 amRNSNet Asset Value(s)
9th Apr 202411:06 amRNSNet Asset Value(s)
8th Apr 202411:22 amRNSNet Asset Value(s)
5th Apr 202410:27 amRNSNet Asset Value(s)
4th Apr 202411:03 amRNSNet Asset Value(s)
3rd Apr 202412:08 pmRNSInvestment in other listed closed-ended inv. fund
3rd Apr 202410:36 amRNSNet Asset Value(s)
2nd Apr 202411:12 amRNSNet Asset Value(s)
28th Mar 202411:44 amRNSCompliance with Market Abuse Regulations
28th Mar 202411:19 amRNSNet Asset Value(s)
27th Mar 202410:59 amRNSNet Asset Value(s)
26th Mar 20243:18 pmRNSDividend Declaration
26th Mar 202411:30 amRNSNet Asset Value(s)
25th Mar 202411:21 amRNSNet Asset Value(s)
22nd Mar 202410:33 amRNSNet Asset Value(s)
21st Mar 202410:23 amRNSNet Asset Value(s)
20th Mar 202410:36 amRNSNet Asset Value(s)
19th Mar 202410:43 amRNSNet Asset Value(s)
18th Mar 202410:48 amRNSNet Asset Value(s)
15th Mar 202410:35 amRNSNet Asset Value(s)
14th Mar 202410:38 amRNSNet Asset Value(s)
13th Mar 202410:27 amRNSNet Asset Value(s)
12th Mar 202411:03 amRNSNet Asset Value(s)
11th Mar 202410:54 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.